Thesis
Quince pivots entirely to LAM-001 (inhaled rapamycin) across BOS and PH-ILD; Phase 2 readouts will determine whether the asset justifies the $187M bet
LAM-001, an inhaled mTOR inhibitor, is being evaluated in bronchiolitis obliterans syndrome post-lung transplant and pulmonary hypertension associated with interstitial lung disease, two indications with limited approved options. The thesis hinges on whether Phase 2 BOS data and Phase 2b PH-ILD data demonstrate efficacy sufficient to support registration, given that current evidence rests on a four-patient Phase 2a PH-ILD cohort. The primary risks are that small exploratory datasets do not replicate in powered trials, and that approved prostacyclin-based therapies like Liquidia's YUTREPIA set a high clinical bar in the PH-ILD space.
Focus
LAM-001 Phase 2b PH-ILD trial initiation and data readout
Q1 2028
Bull
A positive readout would show statistically significant and clinically meaningful improvements in 6-minute walk distance and pulmonary vascular resistance on background therapy, replicating and extending the Phase 2a signals (6MWD +67.4m, PVR -33.9%) in a larger, adequately powered cohort. Functional class improvement sustained across the majority of patients would further de-risk the program and position LAM-001 as a novel mTOR-based add-on therapy in a PH-ILD population with limited mechanistic alternatives, supporting a Phase 3 design and potential partnership discussions.
Bear
The most likely failure mode is regression to the mean from an N=4 Phase 2a dataset — a statistically underpowered signal that does not replicate at scale, with 6MWD and PVR improvements falling below clinically meaningful thresholds in the larger cohort. A second risk is tolerability issues emerging at the population level with chronic inhaled rapamycin exposure (pulmonary inflammation, immunosuppression-related infections) that offset efficacy signals, or a failure to demonstrate additive benefit over background treprostinil therapy, undermining the combination rationale.
Unlock the full thesis for QNCX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.